BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6180095)

  • 1. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer.
    Theriault RL; Hortobagyi GN; Buzdar AU; Levy HB; Hersh EM
    Cancer Treat Rep; 1986 Nov; 70(11):1341-2. PubMed ID: 3768878
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.
    Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE
    Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
    Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
    Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
    [No Abstract]   [Full Text] [Related]  

  • 6. Cortisol induction by poly ICLC: implications for clinical trials of interferon.
    Bever CT; McFarland HF; Levy HB; McFarlin DE
    Ann Neurol; 1988 Feb; 23(2):196-9. PubMed ID: 2454067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent laryngeal papillomatosis with an artificial interferon inducer (poly ICLC).
    Leventhal BG; Kashima H; Levine AS; Levy HB
    J Pediatr; 1981 Oct; 99(4):614-6. PubMed ID: 7277106
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon induction and therapy of brain tumors in rats by poly(ICLC).
    Machida H; Takezawa J; Kuninaka A; Yoshino H; Nakamura O; Takakura K
    Microbiol Immunol; 1982; 26(4):353-8. PubMed ID: 6180284
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)).
    Rettenmaier MA; Berman ML; DiSaia PJ
    Gynecol Oncol; 1986 Jul; 24(3):359-61. PubMed ID: 3721308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of interferon responses to poly ICLC in males and females.
    Bever CT; McFarlin DE; Levy HB
    J Interferon Res; 1985; 5(3):423-8. PubMed ID: 2414373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group.
    Lampkin BC; Levine AS; Levy H; Krivit W; Hammond D
    Cancer Res; 1985 Nov; 45(11 Pt 2):5904-9. PubMed ID: 2414002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of mouse tumor to interferon inducer and radiation.
    Lvovsky EA; Mossman KL; Levy HB; Dritschilo A
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1721-5. PubMed ID: 4030439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver enzyme abnormalities after poly ICLC infusions.
    Hess WA; Bever CT; McFarlin DE
    Cancer Treat Rep; 1985 Nov; 69(11):1342. PubMed ID: 2418967
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I trials of poly(I,C) complexes in advanced cancer.
    Krown SE; Kerr D; Stewart WE; Field AK; Oettgen HF
    J Biol Response Mod; 1985 Dec; 4(6):640-9. PubMed ID: 2418162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of a modified polyinosinic acid--polycytidylic acid complex against herpes simplex keratitis in monkeys (author's transl)].
    Teranishi H
    Nippon Ganka Gakkai Zasshi; 1980 Sep; 84(9):1198-204. PubMed ID: 7223554
    [No Abstract]   [Full Text] [Related]  

  • 16. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator.
    Peters CJ; Reynolds JA; Slone TW; Jones DE; Stephen EL
    Antiviral Res; 1986 Aug; 6(5):285-97. PubMed ID: 2429616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary trial of poly(I,C)-LC in multiple sclerosis.
    McFarlin DE; Bever CT; Salazar AM; Levy HB
    J Biol Response Mod; 1985 Oct; 4(5):544-8. PubMed ID: 2416885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid.
    Droller MJ
    J Urol; 1987 Feb; 137(2):202-6. PubMed ID: 3806804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
    Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG
    Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man.
    Levy HB; Levine AS
    Tex Rep Biol Med; 1981-1982; 41():653-62. PubMed ID: 6189230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.